Black Friday saleUp to 70% OFF
SYNGENE INTERNATIONAL LIMITEDSYNGENE INTERNATIONAL LIMITEDSYNGENE INTERNATIONAL LIMITED

SYNGENE INTERNATIONAL LIMITED

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

SYNGENE trade ideas

SYNGENE INTERNATIONAL : STRENGTH OF 2.5 YRS OF CONSOLIDATIONSyngene International Limited is an India-based contract research company. The Company is engaged in providing services from early discovery and development to commercial manufacturing for small and large molecules and a Market Cap of Rs. 24,500+ Cr. The chart is moving within a limited range since 2020 , for almost 2.5 years. Though the range is high but is limited , from 510 to 680. The stock remained untouched from the relative movements in Pharma Sector as well as market as whole. The stock is now consolidating. When a stock is ready to come out any range, the bottoms get higher and higher as we seen in the chart , the bottoms are getting higher since Jun 2022. We are seeing Symmetrical Triangle Pattern. We see breakout of this pattern last week and since then the stock is consolidating. The next resistance is from 650 to 690, which is stock's life time high. If the stock crosses this level, there is possibility of a new trend , strong trend , with a gained momentum of last 2.5 years. Symmetrical Triangle is completed and is already broken out , pattern is strong , high consolidation of 2.5 Years and 50 EMA Support , all these factors , indicates a break out in of this chart. Entry @ CMP : 609 Targets : 650 , 690 , and if breaks the range (high possibility ) thereafter a new positive trend ... Stop Loss : 605 This analysis is only for education purpose. Please do your own analysis before entering into any trade and trade at your own risk. Best Of Luck !!!
NSE:SYNGENELong
by chakraveer1104
► ADVANCE PATTERN #29: SYNGENE ◄► ADVANCE PATTERN #29: SYNGENE ◄ 📌 Levels are mentioned on chart for ❝Swing trading❞. ☆ Please check the description section ⌨ for early entry level in given stock ₪ to get better Risk to Reward (☈☈) ratio. ☆ Kindly like & share ➥ this pattern. Comment ⎚ with what do you think. Follow me @ tradingview for more updates and like the chart ❤!!! Entry: ▲ 630 SL: ☢ 605 Target: ➚ 705 RR: ☈ 1:3.0 ☆ Thank you. Happy Trading!!! Best Regards, 𝘿𝙧. 𝙎𝙝𝙖𝙢𝙧𝙖𝙟𝙖 𝙉𝙖𝙙𝙖𝙧 𝙋𝙝𝘿 𝙞𝙣 𝙏𝙚𝙘𝙝𝙣𝙤𝙡𝙤𝙜𝙮. ✮ Disclaimer ✮ -------------------------------------------------------- All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual’s trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. ---------------------------------------------------------  
NSE:SYNGENELong
by Profitable_Traders
Syngene international fundamental and technical analysis About company Syngene initiated their operations as a CRO in 1994 with services in chemistry and biology. Syngene International offers integrated solutions across research, development and manufacturing facilities. Sector Overview The Indian pharmaceutical industry is currently valued at $50Bn. India is a large exporter of pharmaceuticals with over 200 countries that receive Indian Pharma exports. The industry growth has been at a CAGR of 9.43% over the last 9 years. Sector Outlook The pharma industry in India is expected to reach $65Bn by 2024 & $130Bn by 2030. India is the world’s largest supplier of generic medications; which account for 20% of the worldwide supply by volume & supply about 60% of the global vaccination demand. Company’s business Syngene International has over 400 active clients and have 15 collaborations with the top 20 pharmaceutical companies. Their sector expertise includes pharmaceuticals, biotech, nutrition, animal health, consumer goods and speciality chemicals. About the segments Syngene International has their presence in the following segments: •Discovery Services •R&D Centres •Development Services •Manufacturing Services Q3 Numbers Revenue up from ₹768 Cr in Q2 to ₹787 Cr in Q3 OPM up from 28% to 29% NPAT up from 102Cr to 110Cr EPS up from ₹5.53 to ₹2.73 Key Highlights: Performance is excluding impact of Remdesivir manufacturing which had high sales growth the during first quarter of the last financial year. No sales have been recorded in 9MFY23. Revenue from operations grew by 23% YoY, excluding Remdesivir; 28% YoY Revenue growth driven by Discovery Service division & manufacturing division; Biologics. Capex for 9M at HKEX:50 mn Started a program of HKEX:30 mn for a new facility & the Capex will be reflected on the books in the next few Qtrs depending on execution EBITDA up 15% YoY Effective tax rate up from 19% to 21.5% YoY; however, they have a MAT credit of ₹160Cr that will be utilised over the next few years & will keep cash outflow for income tax at minimum pertained tax level Depreciation and amortisation up by 21% YoY due to new investments Recently completed facility will offer end-to-end solutions in drug production development & manufacturing for clinical supplies for small & large molecules Expect the completion of additional 24,000 sqft of lab space, a new compound & mgmt facility in the current qtr. Key Strengths Increase in number of collaborations with emerging biopharma companies Expect to start GMP production this quarter with the completion of sterile fill-finish facility for small scale clinical manufacturing FIIs and DIIs have increased holdings QoQ PAT growth at 5% YoY Completed the US FDA, EMEA and MHRA regulatory audits for commercial scale biologics manufacturing facility Received cGMP certifications from regulatory agencies which put them on track to manufacture drug substance on a commercial scale Weakness PAT growth for full year expected to be in single digits Operating EBITDA margin down from 31.7% in Q3 FY22 to 29.4% in Q3 FY23 EBITDA margin for 9M at 29.7% compared to 31% last year Hedge losses in Q3 FY23 at ₹16Cr compared to a hedge gain of ₹20Cr EBITDA growth lower than revenue growth due to low scale and capacity utilisation in manufacturing Material costs up by 6% YoY Lowest dividend yield in pharma sector Finance cost up from ₹9.4Cr to ₹13.7Cr due to rising interest rates; • Numbers and Ratios Market Cap: ₹24,076 Cr. Stock P/E: 55.9 RoCE: 13.3% RoE: 13.6% PEG: 7.25 Price to Sales: 8.14 Int Coverage: 14.3 NPM: 13.9% D/E: 0.31 • Shareholding Pattern Promoter: 64.86% FII: 16.87% DII: 7.03% Public: 10.77% Others: 0.47% Conclusion The company has expanded its facilities and capabilities, receiving regulatory certifications for commercial-scale biologics manufacturing. While operating EBITDA margin has declined, completion of a sterile fill-finish facility & GMP production is expected to boost profitability.
BSE:SYNGENE
by biokon70
31st March || SYNGENE - Intraday Targets Marked #stocks #targetsAnalysis Criteria Used: The analysis for the Intraday Trade ideas, has been done based on Trend analysis and Chart Patterns with Volume Buildups Focus On: 1. Always keeping your Risk Management in play 2. Using a Stop Loss; because it is your Best Friend 3. Always Plan your Trade and stick to your Plan 4. Dont overthink or overanalyse 5. Treat this as your Business and get serious about it #sharemarket #stockmarket #nifty #sensex #investing #trading #nse #bse #stockmarketindia #stocks #indianstockmarket #investment #stockmarketnews #banknifty #finance #money #intraday #intradaytrading #investor #niftyfifty #dalalstreet #sharemarketindia #sharemarketnews #stockmarketinvesting #business #sharemarkettips #stock #india #indiansharemarket #rakeshjhunjhunwala #bhfyp #mumbai #share #wealth #investment #market #invest #trading #investing #finance #FinancialFreedom #investor #trader #stocks #profit #investors #economy #equity #shares #nifty #stockexchange DISCLAIMER: *This is NOT a Tip OR a Recommendation but an analysis for Educational purposes Only ** Please do your own research and/or contact your financial advisor before taking any trading opportunities *** We will not be responsible for your profit or loss **** We are NOT SEBI REGISTERED ______________________ best stocks to buy today best stocks to buy now best stocks to buy best stocks for Intraday tomorrow best stocks for long term investment best stocks to buy today india best stocks for swing trading swing trading strategies swing trading beginners what is swing trading swing trading stocks swing trading stock selection swing trading kya hai nifty analysis nifty view bank nifty analysis top stocks to buy now strong stocks nifty view nifty prediction stock market view tomorrow bank nifty Levels bank nifty prediction share news stock market news best stocks to buy now profit booking stocks multibagger stocks in discount breakout stocks best short term stocks best short term shares next multibagger stocks
NSE:SYNGENE
by TradeRyteStockz
29th March || SYNGENE - Intraday Targets Marked #stocks #targetsFocus On: 1. Always keeping your Risk Management in play 2. Using a Stop Loss; because it is your Best Friend 3. Always Plan your Trade and stick to your Plan 4. Dont overthink or overanalyse 5. Treat this as your Business and get serious about it #sharemarket #stockmarket #nifty #sensex #investing #trading #nse #bse #stockmarketindia #stocks #indianstockmarket #investment #stockmarketnews #banknifty #finance #money #intraday #intradaytrading #investor #niftyfifty #dalalstreet #sharemarketindia #sharemarketnews #stockmarketinvesting #business #sharemarkettips #stock #india #indiansharemarket #rakeshjhunjhunwala #bhfyp #mumbai #share #wealth #investment #market #invest #trading #investing #finance #FinancialFreedom #investor #trader #stocks #profit #investors #economy #equity #shares #nifty #stockexchange DISCLAIMER: . * Please do your own research and/or contact your financial advisor before taking any trading opportunities ** We will not be responsible for your profit or loss *** We are NOT SEBI REGISTERED ______________________ best stocks to buy today best stocks to buy now best stocks to buy best stocks for Intraday tomorrow best stocks for long term investment best stocks to buy today india best stocks for swing trading swing trading strategies swing trading beginners what is swing trading swing trading stocks swing trading stock selection swing trading kya hai nifty analysis nifty view bank nifty analysis top stocks to buy now strong stocks nifty view nifty prediction stock market view tomorrow bank nifty Levels bank nifty prediction share news stock market news best stocks to buy now profit booking stocks multibagger stocks in discount breakout stocks best short term stocks best short term shares next multibagger stocks
NSE:SYNGENE
by TradeRyteStockz